Compare Illumina, Inc. (ILMN) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Chase & Co — how do they compare? Illumina, Inc. trades at $193.06 (market cap $29.12B), while JPMorgan Chase & Co trades at $362.08 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 33× Illumina, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | JPM | |
|---|---|---|
Market Cap | $29.12B | $962.37B |
Sector | Health | Financials |
52-Week High | $205.10 | $362.04 |
52-Week Low | $91.00 | $282.84 |
Enterprise Value | $30.48B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings have shown strength with beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue and net income have grown steadily, with 2025 revenue at $181.85B and net income at $57.05B, though cash flow from operations remains negative. The stock exhibits strong institutional interest and a moderate buy rating from analysts.
The outlook for JPM is positive, supported by robust profitability metrics like an 18.43% ROE and a net income margin of 33.38%. Key risks include geopolitical tensions impacting banking sectors and persistent negative operating cash flows. Upside potential exists if the company meets or exceeds future earnings expectations, with the next catalyst being Q3 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
